Flulaval Non Inferior Adult

FLULAVAL QUADRIVALENT was studied in a randomized, double-blind, active-controlled immunogenicity and safety trial. Subjects aged 18 years and older received FLULAVAL QUADRIVALENT or 1 of 2 formulations of a comparator trivalent influenza vaccine (FLUARIX TIV-1 or TIV-2), each containing an influenza type B virus that corresponded to one of the two B viruses in FLULAVAL QUADRIVALENT (a type B virus of the Victoria lineage or a type B virus of the Yamagata lineage). Immune responses were evaluated in sera obtained 21 days after administration of FLULAVAL QUADRIVALENT or the comparators.¹